Kangmei Pharma | 600518 - Net Income


Kangmei Pharma reported CNY-16.56M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Alaunos Therapeutics USD -1.01M 153K Mar/2026
Avita Medical AUD -11.62M 1.7M Dec/2025
Cspc Pharmaceutical CNY 370.72M 592.81M Dec/2025
Dianthus Therapeutics USD -40.83M 23.6M Mar/2026
Genomma Lab Internacional MXN 374.49M 120.15M Jun/2026
Hypermarcas BRL 347.38M 103.61M Mar/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
IQVIA Holdings USD 256M 18M Jun/2026
Jiangsu Hengrui CNY 2.18B 99.1M Jun/2026
Kangmei Pharma CNY -16.56M 12.74M Mar/2026
Moderna USD -1.34B 517M Mar/2026
Organon & Co USD 108M 38M Jun/2026
Revvity USD 51.82M 11.1M Jun/2026
Sh Fosun Pharma CNY 850.64M 20.18M Jun/2026
Tectonic Therapeutic USD -25.24M 6.02M Mar/2026
Viatris USD -118.8M 295.2M Jun/2026
Wuxi Apptec CNY 6.43B 1.78B Jun/2026
Xeris Pharmaceuticals USD 2.23M 8.85M Mar/2026
Zz Pientze Pharmaceu CNY 349.49M 393.99M Jun/2026